BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26625258)

  • 1. Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy.
    Tanaka Y; Aoyagi K; Minashi K; Komatsuzaki R; Komatsu M; Chiwaki F; Tamaoki M; Nishimura T; Takahashi N; Oda I; Tachimori Y; Arao T; Nishio K; Kitano S; Narumi K; Aoki K; Fujii S; Ochiai A; Yoshida T; Muto M; Yamada Y; Sasaki H
    PLoS One; 2015; 10(12):e0143804. PubMed ID: 26625258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy.
    Wen J; Yang H; Liu MZ; Luo KJ; Liu H; Hu Y; Zhang X; Lai RC; Lin T; Wang HY; Fu JH
    Ann Oncol; 2014 Sep; 25(9):1769-1774. PubMed ID: 24907633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Okamoto H; Fujishima F; Kamei T; Nakamura Y; Ozawa Y; Miyata G; Nakano T; Katsura K; Abe S; Taniyama Y; Sakurai T; Teshima J; Hikage M; Sasano H; Ohuchi N
    BMC Cancer; 2015 Mar; 15():208. PubMed ID: 25880782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of combined endoscopic resection and chemoradiotherapy for esophageal squamous cell carcinoma with submucosal invasion.
    Yoshimizu S; Yoshio T; Ishiyama A; Tsuchida T; Horiuchi Y; Omae M; Hirasawa T; Asari T; Chin K; Fujisaki J
    Dig Liver Dis; 2018 Aug; 50(8):833-838. PubMed ID: 29477349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of immune-based therapy with cytotoxic T lymphocyte and molecular targeting therapy for HER2 in esophageal squamous cell carcinoma].
    Mimura K; Izawa S; Siba S; Maruyama T; Watanabe M; Kawaguchi Y; Fuji H; Kono K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1918-20. PubMed ID: 22202238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
    Gombodorj N; Yokobori T; Tanaka N; Suzuki S; Kuriyama K; Kumakura Y; Yoshida T; Sakai M; Sohda M; Baatar S; Miyazaki T; Nishiyama M; Shirabe K; Kuwano H
    J Surg Oncol; 2018 Jul; 118(1):101-108. PubMed ID: 30098297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Chen MQ; Lin QL; Chen YG; Guo JH; Xu BH; Tian Y
    J Chin Med Assoc; 2017 Oct; 80(10):636-643. PubMed ID: 28716602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy.
    Zhang J; Jiao Q; Kong L; Yu J; Fang A; Li M; Yu J
    Thorac Cancer; 2018 Jun; 9(6):726-735. PubMed ID: 29675925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma.
    Chang WL; Lai WW; Kuo IY; Lin CY; Lu PJ; Sheu BS; Wang YC
    J Gastroenterol; 2017 Jun; 52(6):705-714. PubMed ID: 27671002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy.
    Fujishima F; Taniyama Y; Nakamura Y; Okamoto H; Ozawa Y; Ito K; Ishida H; Konno-Kumagai T; Kasajima A; Taniuchi S; Watanabe M; Kamei T; Sasano H
    Dis Esophagus; 2018 Jul; 31(7):. PubMed ID: 29346536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.
    Wen J; Luo K; Liu H; Liu S; Lin G; Hu Y; Zhang X; Wang G; Chen Y; Chen Z; Li Y; Lin T; Xie X; Liu M; Wang H; Yang H; Fu J
    Ann Surg; 2016 May; 263(5):942-8. PubMed ID: 26445467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZNF750 Expression as a Novel Candidate Biomarker of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma.
    Otsuka R; Akutsu Y; Sakata H; Hanari N; Murakami K; Kano M; Takahashi M; Matsumoto Y; Sekino N; Yokoyama M; Iida K; Matsubara H
    Oncology; 2017; 93(3):197-203. PubMed ID: 28558382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications.
    Ashida A; Boku N; Aoyagi K; Sato H; Tsubosa Y; Minashi K; Muto M; Ohtsu A; Ochiai A; Yoshida T; Yoshida S; Sasaki H
    Int J Oncol; 2006 Jun; 28(6):1345-52. PubMed ID: 16685435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre- versus postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Hsu PK; Chen HS; Liu CC; Huang CS; Hsieh CC; Hsu HS; Wu SC
    J Thorac Cardiovasc Surg; 2017 Aug; 154(2):732-740.e2. PubMed ID: 28457536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD24 and CK4 are upregulated by SIM2, and are predictive biomarkers for chemoradiotherapy and surgery in esophageal cancer.
    Takashima K; Fujii S; Komatsuzaki R; Komatsu M; Takahashi M; Kojima T; Daiko H; Minashi K; Chiwaki F; Muto M; Sasaki H; Yano T
    Int J Oncol; 2020 Mar; 56(3):835-847. PubMed ID: 32124945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer.
    Zhang JL; Wang HY; Yang Q; Lin SY; Luo GY; Zhang R; Xu GL
    World J Gastroenterol; 2015 Apr; 21(14):4240-7. PubMed ID: 25892874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation.
    Hsu FM; Cheng JC; Chang YL; Lee JM; Koong AC; Chuang EY
    Sci Rep; 2015 May; 5():10291. PubMed ID: 25980316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.